Predict your next investment

HEALTHCARE | Drug Development
ganlee.com

See what CB Insights has to offer

Total Raised

$449.52M

Investors Count

8

Deal Terms

7

Gan & Lee Pharmaceuticals Funding, Gan & Lee Pharmaceuticals Valuation & Gan & Lee Pharmaceuticals Revenue

9 Fundings

Gan & Lee Pharmaceuticals's latest funding round was a IPO for $359.47M on June 29, 2020.

Gan & Lee Pharmaceuticals's valuation in November 2014 was $1,635.32M.

Gan & Lee Pharmaceuticals's latest post-money valuation is from June 2020.

Sign up for a free 30-day trial to see Gan & Lee Pharmaceuticals's valuations in June 2020 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

6/29/2020

IPO

$359.47M

$99M

$0.00B

((9.99x))

FY 1234

3

1/1/2015

Series E

$99M

$0.00B

((9.99x))

FY 1234

10

11/1/2014

Series D

$99M

$1,635.32M

$0.00B

((9.99x))

FY 1234

10

2/1/2012

Series C

$99M

$0.00B

((9.99x))

FY 1234

10

5/14/2011

Series B

$99M

$0.00B

((9.99x))

FY 1234

10

Date

6/29/2020

1/1/2015

11/1/2014

2/1/2012

5/14/2011

Round

IPO

Series E

Series D

Series C

Series B

Amount

$359.47M

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$1,635.32M

Revenue

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

$0.00B

((9.99x))

FY 1234

Sources

3

10

10

10

10

Gan & Lee Pharmaceuticals Deal Terms

7 Deal Terms

Gan & Lee Pharmaceuticals's deal structure is available for 7 funding rounds, including their IPO from June 29, 2020.

Round

IPO

Series E

Series D

Series C

Series B

Funding Date

$99M

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

$99M

$99M

$99M

$99M

Post-Money Valuation

$99M

$99M

$99M

$99M

$99M

Amount Raised

$99M

$99M

$99M

$99M

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

IPO

$99M

$99M

$99M

$99M

$99M

$99M

Series E

$99M

$99M

$99M

$99M

$99M

$99M

Series D

$99M

$99M

$99M

$99M

$99M

$99M

Series C

$99M

$99M

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

$99M

$99M

Gan & Lee Pharmaceuticals Investors

8 Investors

Gan & Lee Pharmaceuticals has 8 investors. Qiming Venture Partners invested in Gan & Lee Pharmaceuticals's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/1/2009

1/1/2015

5
Series A - II, Series B (2011), Series E (2015), Series C (2012), Series A (2009)

Venture Capital

China

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Asset/Investment Management

China

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Other

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Other

China

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Corporation

China

First funding

9/1/2009

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

1/1/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Rounds

5
Series A - II, Series B (2011), Series E (2015), Series C (2012), Series A (2009)

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Type

Venture Capital

Asset/Investment Management

Other

Other

Corporation

Location

China

China

China

China

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.